摘要
抗肿瘤治疗(主要是药物治疗)常常引起恶心呕吐,不仅给患者带来明显不适,加重其心理、精神负担,还会影响抗肿瘤治疗的依从性和整体疗效。这种恶心呕吐大多持续时间较长,可延续至给药后120 h,甚至更长。然而,临床上常用止吐药物的半衰期较短,不能通过单次用药覆盖整个风险期,亟需更长效、更便捷和更安全的药物,助力抗肿瘤治疗相关恶心呕吐的全程管理。注射用磷罗拉匹坦帕洛诺司琼是一种新型双通道、超长效止吐针剂,已经获得国家药品监督管理局批准上市,用于预防成人高度致吐性化疗(HEC)引起的急性和迟发性恶心和呕吐。该药物同时靶向神经激肽-1(NK-1)受体和5-羟色胺3(5-HT_(3))受体,实现双重阻断,且其半衰期长达188 h,单次给药即可覆盖一个治疗周期的抗肿瘤治疗相关恶心呕吐的急性期、延迟期和超延迟期。为了规范注射用磷罗拉匹坦帕洛诺司琼的临床应用,中国临床肿瘤学会抗肿瘤药物安全管理专家委员会和肿瘤支持与康复治疗专家委员会共同组织了专家组,基于最新研究证据并且结合临床经验,反复讨论后制定了本指导原则,以供广大医师参考。
TAnti-tumor therapy(mainly including drug therapy)often causes the nausea and vomiting,which not only brings obvious discomfort to cancer patients,increases their psychological and mental burden,but also affects the compliance of anti-tumor treatment and the overall therapeutic efficacy.Those nausea and vomiting symptoms often last for a quite long time,usually persisting for more than 120 hours after administration of anti-tumor drugs.However,now clinical commonly used antiemetic drugs have a shorter half-life time,making it difficult to cover the entire risk period of nausea and vomiting with a single anti–tumor treatment cycle.Thus there is an urgent as well as huge unmet need for longer acting,more convenient and safe drugs,to facilitate whole-process management of anti-tumor therapy induced nausea and vomiting in clinical practice.Fosrolapitant and palonosetron hydrochloride for injection is a novel dual-channel,ultra-long acting antiemetic drug approved by the Chinese National Medical Products Administration(NMPA)on May 27,2025,for the effective prevention of acute and delayed nausea and vomiting caused by the adult highly emetic chemotherapy(HEC)drug or regimen.That drug targets both the neurokinin-1(NK-1)receptor and the 5-hydroxytryptamine 3(5-HT_(3))receptor,achieving strong and dual blockade of those two emetic targets in same time.Its half-life time is up to 188 hours,thus a single administration can cover the acute,delayed,and ultra-delayed phases of nausea and vomiting related to a single anti-cancer treatment cycle.In order to standardize the clinical application of fosrolapitant and palonosetron hydrochloride for injection,Expert Committee on Safety Management of Antitumor Therapy and Expert Committee on Supportive and Rehabilitation Therapy for Tumors,Chinese Society of Clinical Oncology(CSCO)jointly organized an expert group.Based on the latest research evidence and clinical experience,they repeatedly deliberated to formulate these guidelines for reference by physicians.
作者
中国临床肿瘤学会抗肿瘤药物安全管理专家委员会
中国临床肿瘤学会肿瘤支持与康复治疗专家委员会
张力
梁军
潘宏铭
罗素霞
王杰军
杨帆
廖峰
陈映霞
马军
秦叔逵
Expert Committee on Safety Management of Antitumor Therapy,Chinese Society of Clinical Oncology;Expert Committee on Supportive and Rehabilitation Therapy for Tumors,Chinese Society of Clinical Oncology;ZHANG Li;LIANG Jun;PAN Hongming;LUO Suxia;YANG Fan;LIAO Feng;CHEN Yinxia;MA Jun;QIN Shukui
出处
《临床肿瘤学杂志》
2025年第12期1213-1218,共6页
Chinese Clinical Oncology
关键词
抗肿瘤治疗
恶心
呕吐
磷罗拉匹坦帕洛诺司琼
anti-tumor therapy
nausea
vomiting
fosrolapitant and palonosetron hydrochloride injection
